ACADIA Names CCO

Terrence Moore has been named executive vice president and chief commercial officer of ACADIA Pharmaceuticals. He will report to chief executive officer, Uli Hacksell, Ph.D., and will be responsible for leading ACADIA’s commercial activities.

“Terry is an exceptional individual who brings a wealth of commercial experience to ACADIA from a variety of senior roles at several leading pharmaceutical companies. He has made key contributions to the building of multi-billion dollar brands in the CNS field, including Prozac, Zyprexa, Risperdal, and Effexor XR,” said Dr. Hacksell. ACADIA’s lead candidate is pimavanserin, a potential first-in-class treatment for Parkinson’s disease psychosis, currently in Phase III.

Mr. Moore has more than 25 years of experience as a senior member of sales and marketing teams at several pharma companies. Most recently, Mr. Moore was a principal of Cook-Moore Consulting and, before founding the firm, served as vice president at Transcept Pharmaceuticals, where he was responsible for commercial strategy, business development and commercial alliance activities. Previously, Mr. Moore served as vice president, U.S. Head of Neuroscience Marketing at Organon BioSciences and was responsible for the creation and building of its Neuroscience Business Unit. He also served as vice president, U.S. Marketing, Effexor XR, as well as vice president, Global Strategy Depression Portfolio at Wyeth Pharmaceuticals. Earlier, Mr. Moore held senior management positions at J&J, where he helped to launch Risperdal for additional indications in the U.S., and at Eli Lilly, where he held various sales and marketing roles over 11 years, including Zyprexa brand manager.

“I am very pleased to be joining an organization dedicated to meeting the needs of patients suffering from neurological disorders and those who are responsible for providing their care,” said Mr. Moore. “It is an exciting time at ACADIA as the company advances toward an NDA submission for pimavanserin and accelerates its pre-commercial activities. I look forward to working with the ACADIA team to achieve the goal of bringing this innovative product to market and building a successful pimavanserin franchise.”